NO20052751L - Oftalmisk preparat for behandling av okulaer hypertensjon. - Google Patents

Oftalmisk preparat for behandling av okulaer hypertensjon.

Info

Publication number
NO20052751L
NO20052751L NO20052751A NO20052751A NO20052751L NO 20052751 L NO20052751 L NO 20052751L NO 20052751 A NO20052751 A NO 20052751A NO 20052751 A NO20052751 A NO 20052751A NO 20052751 L NO20052751 L NO 20052751L
Authority
NO
Norway
Prior art keywords
treatment
ocular hypertension
ophthalmic preparation
compounds
eye
Prior art date
Application number
NO20052751A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052751D0 (no
Inventor
James B Doherty
Meng-Hsin Chen
Luping Liu
Swaminathan R Natarajan
Robert M Tynebor
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20052751D0 publication Critical patent/NO20052751D0/no
Publication of NO20052751L publication Critical patent/NO20052751L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/65031Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20052751A 2002-11-08 2005-06-07 Oftalmisk preparat for behandling av okulaer hypertensjon. NO20052751L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42480802P 2002-11-08 2002-11-08
US50009103P 2003-09-04 2003-09-04
PCT/US2003/035080 WO2004043933A1 (en) 2002-11-08 2003-11-04 Ophthalmic compositions for treating ocular hypertension

Publications (2)

Publication Number Publication Date
NO20052751D0 NO20052751D0 (no) 2005-06-07
NO20052751L true NO20052751L (no) 2005-06-07

Family

ID=32314559

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052751A NO20052751L (no) 2002-11-08 2005-06-07 Oftalmisk preparat for behandling av okulaer hypertensjon.

Country Status (22)

Country Link
US (2) US7196082B2 (ja)
EP (1) EP1562909B1 (ja)
JP (2) JP4456072B2 (ja)
KR (1) KR20050072805A (ja)
AR (1) AR041991A1 (ja)
AU (2) AU2003287506B8 (ja)
BR (1) BR0316040A (ja)
CA (1) CA2505086C (ja)
CL (1) CL2003002293A1 (ja)
DO (1) DOP2003000747A (ja)
EC (1) ECSP055781A (ja)
HR (1) HRP20050409A2 (ja)
IS (1) IS7822A (ja)
MA (1) MA27497A1 (ja)
MX (1) MXPA05004889A (ja)
NO (1) NO20052751L (ja)
NZ (1) NZ539593A (ja)
PE (1) PE20040692A1 (ja)
PL (1) PL377172A1 (ja)
RU (1) RU2005117627A (ja)
TW (1) TWI250873B (ja)
WO (2) WO2004043932A1 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040028469A (ko) 2002-09-30 2004-04-03 엘지전자 주식회사 1 회 기록 가능한 광디스크의 디펙트 영역 관리방법
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
AU2004272546B2 (en) * 2003-09-04 2007-10-18 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
AU2005274972A1 (en) * 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
NZ570846A (en) * 2006-01-31 2011-08-26 Array Biopharma Inc Kinase inhibitors and methods of use thereof
CA2644716A1 (en) * 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
WO2010051561A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
EP2968304B1 (en) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
DK3137168T3 (da) 2014-04-30 2022-03-21 Univ Columbia Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse
CN104211638A (zh) * 2014-08-13 2014-12-17 李增 一种脂肪氨基取代的芸香碱类衍生物及其制备和作为抗阿尔兹海默症的药物中的应用
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
WO1989010757A1 (en) 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis New ophthalmic preparation for treating glaucoma
DE68929435T2 (de) * 1988-09-06 2003-07-17 Pharmacia Ab Prostaglandinderivate zur Behandlung des grünen Stars oder einer okularen Hypertension
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3208210B2 (ja) * 1993-03-17 2001-09-10 旭化成株式会社 結晶性芳香族ポリカーボネートプレポリマーの製造方法及び芳香族ポリカーボネートの製造方法
JPH08511024A (ja) 1993-06-08 1996-11-19 バイディ ファーマシューティカルズ 眼内圧を低下させる方法および組成物
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
US6586468B1 (en) 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
CN1413190A (zh) 1999-12-22 2003-04-23 辉瑞产品公司 治疗骨质疏松的ep4受体选择性激动剂
EP1251862B1 (en) 2000-01-18 2008-10-01 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US6956036B1 (en) * 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
AU2001216072A1 (en) 2000-03-17 2001-10-03 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
BR0017163A (pt) 2000-03-17 2003-01-14 Alcon Inc Derivados 5-hidróxi-indazol para tratamento do glaucoma
EP1186287A1 (en) 2000-03-31 2002-03-13 Toray Industries, Inc. Hair growth or hair formation controlling agents
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
IL155368A0 (en) 2000-11-27 2003-11-23 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis
FR2827861B1 (fr) 2001-07-27 2004-04-02 Aventis Pharma Sa Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie

Also Published As

Publication number Publication date
PE20040692A1 (es) 2004-10-08
AU2003287506A1 (en) 2004-06-03
IS7822A (is) 2005-04-25
RU2005117627A (ru) 2006-01-20
JP4456072B2 (ja) 2010-04-28
AR041991A1 (es) 2005-06-08
NZ539593A (en) 2006-12-22
EP1562909A1 (en) 2005-08-17
NO20052751D0 (no) 2005-06-07
TWI250873B (en) 2006-03-11
AU2003287506B2 (en) 2009-04-23
KR20050072805A (ko) 2005-07-12
PL377172A1 (pl) 2006-01-23
CL2003002293A1 (es) 2005-01-14
ECSP055781A (es) 2005-09-20
JP2010006825A (ja) 2010-01-14
EP1562909B1 (en) 2012-06-27
JP5061293B2 (ja) 2012-10-31
JP2006508190A (ja) 2006-03-09
CA2505086A1 (en) 2004-05-27
US20040097575A1 (en) 2004-05-20
AU2003287506B8 (en) 2009-05-28
BR0316040A (pt) 2005-09-13
MXPA05004889A (es) 2005-07-22
MA27497A1 (fr) 2005-08-01
WO2004043932A1 (en) 2004-05-27
HRP20050409A2 (en) 2006-02-28
WO2004043933A1 (en) 2004-05-27
DOP2003000747A (es) 2004-05-31
CA2505086C (en) 2009-08-25
TW200501949A (en) 2005-01-16
US20070129418A1 (en) 2007-06-07
US7196082B2 (en) 2007-03-27
AU2003286884A1 (en) 2004-06-03
US7547720B2 (en) 2009-06-16

Similar Documents

Publication Publication Date Title
NO20052751L (no) Oftalmisk preparat for behandling av okulaer hypertensjon.
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
DK1553953T3 (da) Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom
WO2003047513A3 (en) Method for treating ocular hypertension
WO2007108968A3 (en) Ophthalmic compositions for treating ocular hypertension
LU92058I2 (fr) Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®)
DK1239774T3 (da) Apparat til behandling af öjensygdomme
WO2008008330A3 (en) Deuterated ocular solutions for ltk and other surgical eye procedures
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
CA2440764A1 (en) Combination of brimonidine and timolol for topical ophthalmic use
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
AU2003223224A1 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
DE60334905D1 (de) 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
WO2003105781A3 (en) OPHTHALMIC COMPOSITIONS FOR TREATING EYE HYPERTENSION
EP1251862A4 (en) ORTHALMOLOGICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
WO2006020003A3 (en) Ophthalmic compositions for treating ocular hypertension
BR0017163A (pt) Derivados 5-hidróxi-indazol para tratamento do glaucoma
WO2007146136A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2006007227A3 (en) Abnormal cannabidiols for lowering intraocular pressure
ATE511506T1 (de) Thiopen-derivate als wirkstoffe gegen okulare hypotonie